S. Kennedy

发表

A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer

M. Nicolson, F. Blackhall, P. Schmid, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

R. Herbst, J. Heymach, J. Hou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

The effect of food on and the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects.

R. Smith, J. Robertson, S. Kennedy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results.

R. Herbst, J. Heymach, D. Prager, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

Paul D. Martin, S. Oliver, J. Read, 2011, Drugs in R&D.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

R. Herbst, A. Ryan, H. Mann, 2009, Clinical Cancer Research.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

R. Govindan, M. Ranson, N. Rizvi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Paul D. Martin, S. Oliver, M. Hutchison, 2012, Clinical therapeutics.

The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects

P. Ghahramani, S. Oliver, T. Hammett, 2005 .

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

R. Herbst, N. Saijo, W. Eberhardt, 2009 .

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Paul D. Martin, S. Oliver, M. Hutchison, 2012, Clinical therapeutics.

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

P. Langmuir, S. Korfee, S. Kennedy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.